Skip to main content
. 2022 May 26;113(7):2272–2287. doi: 10.1111/cas.15378

FIGURE 3.

FIGURE 3

The correlation between the efficacy of lenvatinib and fibroblast growth factor receptor 4 (FGFR4) expression in patients with hepatocellular carcinoma. Correlation between FGFR4 expression and sensitivity to lenvatinib. Progression‐free survival in patients with FGFR4‐positive and FGFR4‐negative lesions